A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1227-1231, 2007.
Article
Dans Chinois
| WPRIM
| ID: wpr-268200
ABSTRACT
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase, originally identified as a protein kinase by its ability to phosphorylate and inactivate glycogen synthase. It was found that the overexpression of GSK-3 is associated with some diseases, such as diabetes, Alzheimer disease and other neurodegenerative diseases. Some pharmacological inhibitors of GSK-3 have been demonstrated to mimic insulin signaling, adjust glycogen synthesis and glucose metabolism, and improve insulin resistance. So GSK-3 inhibitors are realized as a new approach of treating diabetes. This review summarizes current advances in research of GSK-3 inhibitors as a new therapeutic approach for diabetes.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Physiologie
/
Glycémie
/
Insulinorésistance
/
Transduction du signal
/
Glycogen Synthase Kinase 3
/
Utilisations thérapeutiques
/
Diabète
/
Traitement médicamenteux
/
Antienzymes
/
Maladie d'Alzheimer
Limites du sujet:
Animaux
/
Humains
langue:
Chinois
Texte intégral:
Acta Pharmaceutica Sinica
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS